What stands out: Enforcement focus on mass-marketing, not patient-specific compounding Clear limits on advertising claims, including prohibitions on calling compounded products generic, the same as, or clinically proven Reinforcement of FD&C Act authorities, including misbranding provisions and Section 503A requirements Shift as shortages resolve, removing the legal basis for broad compounding of GLP-1 drugs Expanded compliance tools, including warning letters, seizure, and injunction where violations persist Bottom line: This signals a firmer FDA posture as the GLP-1 market matures, reinforcing long-standing distinctions between FDA-approved drugs and unapproved compounded preparations, particularly when promoted directly to consumers at scale
Its important to note that using semaglutide and liraglutide together is not recommended
For mild localized irritation, an over-the-counter hydrocortisone cream (0.5% to 1%) may help
Instead of following a standard rapid-escalation schedule, our clinical protocol focuses on identifying a dose that provides meaningful health benefits, while being specifically designed to minimize side effects so you can maintain your quality of life
Choose approaches that work with your body instead of against it